Published in Best Pract Res Clin Gastroenterol on January 01, 2008
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology (2013) 4.20
Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology (2009) 3.67
Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol (2005) 3.13
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A (2007) 2.27
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol (2008) 2.16
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol (2009) 2.16
Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol (2011) 2.07
Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol (2013) 2.05
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol (2002) 1.82
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr (2008) 1.78
Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis (2009) 1.65
Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol (2009) 1.56
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis (2013) 1.51
Markers of Bone Metabolism in Obese Individuals Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg (2015) 1.41
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.41
Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem (2010) 1.17
Vesicle associated membrane protein (VAMP)-7 and VAMP-8, but not VAMP-2 or VAMP-3, are required for activation-induced degranulation of mature human mast cells. Eur J Immunol (2008) 1.15
Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol (2005) 1.13
Cutting-edge technology. III. Imaging and the gastrointestinal tract: mapping the human enteric nervous system. Am J Physiol Gastrointest Liver Physiol (2002) 1.10
Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr (2011) 1.09
Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest (2012) 1.07
Role of activator protein 1, nuclear factor-kappaB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol (2003) 1.04
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis (2011) 1.04
Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol (2007) 1.04
Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci (2012) 1.03
The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest (2002) 1.03
Summary of the First International Gastrointestinal Eosinophil Research Symposium. J Pediatr Gastroenterol Nutr (2007) 1.03
Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis. J Allergy Clin Immunol (2012) 1.02
Pre- and postoperative nutritional deficiencies in obese patients undergoing laparoscopic sleeve gastrectomy. Obes Surg (2012) 1.02
Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol (2008) 1.01
Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One (2013) 1.01
Eosinophilic esophagitis: the endoscopist's enigma. Gastrointest Endosc (2006) 1.00
Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis. Clin Nutr (2002) 0.98
Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res (2010) 0.97
Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem (2012) 0.97
Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal (2011) 0.96
SNAP-23 and syntaxin-3 are required for chemokine release by mature human mast cells. Mol Immunol (2011) 0.96
IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J Immunol (2005) 0.95
Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J (2012) 0.94
A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. Eur J Nutr (2012) 0.92
Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol (2003) 0.91
Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. Vet Immunol Immunopathol (2006) 0.91
Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol (2013) 0.91
Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol (2004) 0.91
Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Understanding the reward system functioning in anorexia nervosa: crucial role of physical activity. Biol Psychol (2013) 0.90
Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab Invest (2011) 0.90
Isolation, culture, and characterization of intestinal mast cells. Methods Mol Biol (2006) 0.89
Placebo and other interventions in asthma. N Engl J Med (2011) 0.89
Analysis of the intestinal microbiota using SOLiD 16S rRNA gene sequencing and SOLiD shotgun sequencing. BMC Genomics (2013) 0.88
Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis (2011) 0.87
Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem (2012) 0.87
Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis. J Allergy Clin Immunol (2010) 0.87
Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood (2002) 0.86
Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis (2010) 0.86
Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptor-dependent mediator release. Eur J Immunol (2002) 0.86
Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J Nutr (2009) 0.85
beta2-Adrenoceptor-mediated suppression of human intestinal mast cell functions is caused by disruption of filamentous actin dynamics. Eur J Immunol (2005) 0.85
Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol (2007) 0.85
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis (2015) 0.84
Olfactory deficits in patients with anorexia nervosa. Eur Eat Disord Rev (2010) 0.84
Human intestinal mast cells are a potent source of multiple chemokines. Cytokine (2012) 0.84
Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int (2014) 0.83
Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther (2011) 0.83
Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes. Digestion (2013) 0.82
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut (2010) 0.82
Dietary pattern and leisure time activity of overweight and normal weight children in Germany: sex-specific differences. Nutr J (2013) 0.82
Selective activation of human intestinal mast cells by Escherichia coli hemolysin. J Immunol (2008) 0.82
Sex-specific differences in the development of acute alcohol-induced liver steatosis in mice. Alcohol Alcohol (2013) 0.82
The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr (2004) 0.81
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis (2010) 0.81
A low fructose diet in the treatment of pediatric obesity: a pilot study. Pediatr Int (2011) 0.81
The circadian clock is functional in eosinophils and mast cells. Immunology (2013) 0.80
Treatment of eosinophilic esophagitis: diet, drugs, or dilation? Gastroenterology (2012) 0.80
Cytotoxic T cells are preferentially activated in the duodenal epithelium from patients with florid coeliac disease. J Pathol (2005) 0.80
Isolation and characterization of human intestinal mast cells. Methods Mol Biol (2015) 0.79
Eosinophilic esophagitis and allergy. Dig Dis (2014) 0.79
Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells. Eur J Nutr (2012) 0.78
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis (2015) 0.78
Mast cell dynamics and involvement in the development of peritoneal adhesions in the rat. Life Sci (2002) 0.78
Akt cross-links IL-4 priming, stem cell factor signaling, and IgE-dependent activation in mature human mast cells. Mol Immunol (2010) 0.78
Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis. J Allergy Clin Immunol (2008) 0.77
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm Bowel Dis (2010) 0.77
[Status of alternative medicine in Crohn disease and ulcerative colitis patents: a questionnaire survey]. Forsch Komplementarmed Klass Naturheilkd (2005) 0.77
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol (2017) 0.76
Interferon-γ regulates growth and controls Fcγ receptor expression and activation in human intestinal mast cells. BMC Immunol (2014) 0.76
Differences in the prevalence of metabolic disorders between prepubertal boys and girls from 5 to 8 years of age. Acta Paediatr (2014) 0.76
Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn's disease tissue. Immunology (2014) 0.76
Oral immunotherapy for egg allergy in children. N Engl J Med (2012) 0.76
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment. J Pediatr Gastroenterol Nutr (2016) 0.76
Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies. Dig Dis (2016) 0.76
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis (2017) 0.75
Dmbt1 does not affect a Western style diet-induced liver damage in mice. J Clin Biochem Nutr (2013) 0.75